The legal experts recently discussed the mechanics of direct-to-patient (DTP) and direct-to-employer (DTE) models.

BioXconomy presents the Asia biopharma and healthcare dealmaking highlights for the week ending October 11, 2026.

The company has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 ...

Investor risk aversion was identified as the leading constraint on biotech investment, cited by 64% of respondents. In Europe ...

In a recent presentation at the Medicaid Drug Rebate Program Summit, Lorilyn Rosales-Menzel, associate general counsel for US ...

This investment hesitation represents more than financial calculations—it threatens the pipeline of future therapies. “The ...

Prader-Willi syndrome is a rare genetic condition that can present from birth. Its occurrence is around 1 in 15,000, and tens ...

Pharma industry is navigating its biggest drug pricing compliance overhaul since 2006, as CMS’ 2026 Physician Fee Schedule ...

Viatris will acquire all outstanding shares of Pacira's common stock for $36.50 per share, representing an aggregate equity ...

This webinar will explore integrating the Pfenex Expression Technology® platform directly into the antibody screening ...

Partnership aims to improve patient access and adherence through mobile-first engagement platform for life sciences firms ...

Agency plans extensive changes to Clinical Trials Information System to enable faster study assessments and greater ...